<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Increased pulse pressure</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Increased pulse pressure</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Increased pulse pressure</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Raymond R Townsend, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">George L Bakris, MD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John P Forman, MD, MSc</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Karen Law, MD, FACP</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 31, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Typical blood pressure measurements include a systolic and diastolic value, which represent the extremes of pressure fluctuation within the circulation during the cardiac cycle. There has been much debate about which increased value alone, either systolic or diastolic hypertension, is more predictive of adverse cardiovascular outcomes in various patient populations. (See  <a class="medical medical_review" href="/z/d/html/3879.html" rel="external">"Blood pressure measurement in the diagnosis and management of hypertension in adults"</a>.)</p><p>Mean arterial pressure measurements, which provide another indication of overall circulatory pressure load, have also been proposed as predictive for adverse cardiovascular outcomes. This is either determined directly by arterial catheterization or can be estimated by formulas (such as diastolic blood pressure + 1/3 x [systolic pressure – diastolic pressure]). However, the mean arterial pressure provides less discriminatory power as patients age. The diastolic pressure peaks at and subsequently declines after the age of 55 years, while the systolic pressure rises relentlessly with each decade of life [<a href="#rid1">1</a>]. Thus, depending upon the respective changes in systolic and diastolic pressures with older age, the mean arterial pressure may actually tend to change less as individuals age.</p><p>Since the diastolic pressure in a population rises until the sixth decade and then subsequently declines with increasing age, an elevation in the diastolic pressure alone is less useful as an outcome predictor in older patients. Increasing emphasis has therefore been placed upon systolic pressure alone as the most useful predictor of cardiovascular disease in these individuals. (See  <a class="medical medical_review" href="/z/d/html/3863.html" rel="external">"Treatment of hypertension in older adults, particularly isolated systolic hypertension"</a>.)</p><p>Several guidelines have supported the use of systolic blood pressure and strongly encourage the use of systolic blood pressure goals in antihypertensive treatment [<a href="#rid2">2-4</a>].</p><p>There is also an enhanced risk for cardiovascular events associated with increases in pulse pressure (defined below). Although most trials of blood pressure lowering use systolic or diastolic blood pressure as therapeutic goals, consideration of the pulse pressure may add to the clinical reasoning about whether to add or titrate medication further when, for example, diastolic blood pressure values are below goal but systolic blood pressure values remain elevated.</p><p>This topic review will discuss the factors that determine pulse pressure and will present some of the evidence for and against the suggestion that there is an independent link between an increased pulse pressure and adverse cardiovascular outcomes.</p><p class="headingAnchor" id="H2"><span class="h1">CLINICAL PERSPECTIVE</span><span class="headingEndMark"> — </span>The pulse pressure is <strong>defined</strong> as the systolic minus the diastolic pressure. This value appears, at least in some epidemiologic studies, to be superior in predictive value to the systolic or diastolic values alone. (See <a class="local">'Increased pulse pressure and adverse outcomes'</a> below.)</p><p>However, given the predictive information from the systolic and diastolic pressures, it is unclear, at first glance, that the pulse pressure provides additional independent information. Among patients with a diastolic pressure of 95 mmHg, for example, a higher pulse pressure simply means that there is a higher systolic pressure which itself is a risk factor for worse outcomes. The pulse pressure also must be considered in the context of the absolute values of systolic and diastolic pressures (eg, a blood pressure of 120/80 mmHg is not equivalent in risk to 160/120 mmHg) [<a href="#rid5">5</a>].</p><p class="headingAnchor" id="H2406867720"><span class="h2">Normal pulse pressure</span><span class="headingEndMark"> — </span>There is no widely accepted definition of "normal" pulse pressure. However, beginning with the definition that "normal" blood pressure is &lt;120/&lt;80 mmHg [<a href="#rid2">2</a>], a reasonable definition for normal pulse pressure is &lt;40 mmHg. Pulse pressure is typically higher in people with hypertension. In most studies of such patients, individuals in the lowest quartile of pulse pressure, although not technically "normal," had the lowest cardiovascular risk (<a class="graphic graphic_table graphicRef139697" href="/z/d/graphic/139697.html" rel="external">table 1</a>). </p><p class="headingAnchor" id="H3"><span class="h2">Pulse pressure and age</span><span class="headingEndMark"> — </span>To better understand the purported associations among pulse pressure, systolic pressure, diastolic pressure, risk of cardiovascular disease, and increasing age, it is worthwhile to review age-related changes in blood pressure measurements and the risk for cardiovascular disease as individuals age.</p><p>In patients less than 55 years of age, the diastolic and systolic blood pressures are both predictive of adverse events from cardiovascular disease. However, because the diastolic blood pressure declines on average after the age of 55 years, its predictive value is diminished in older patients.</p><p>By comparison, the systolic pressure continues to rise with every decade of life, resulting in the maintenance of its predictive value for cardiovascular disease. Thus, in older patients, the association between an increased systolic pressure alone and cardiovascular disease becomes much stronger than that observed with the diastolic blood pressure alone.</p><p>With increasing age, the pulse pressure correlates more closely with the systolic pressure than with the diastolic pressure and is therefore also a good predictor of cardiovascular disease among older adults. An additional benefit of the pulse pressure is that it incorporates both the systolic pressure increase and the diastolic decrease that is observed with age. In some cases, this measurement has superior predictive power to that observed with the systolic pressure alone. (See <a class="local">'Increased pulse pressure and adverse outcomes'</a> below.)</p><p class="headingAnchor" id="H4"><span class="h1">FACTORS RESULTING IN INCREASED PULSE PRESSURE</span><span class="headingEndMark"> — </span>Increases in the pulse pressure result from changes in elasticity and stiffening of arteries [<a href="#rid6">6</a>], factors that increase systolic pressure and/or decrease the diastolic pressure. Since the changes in pulse pressure are mostly related to changes in systolic blood pressure, factors affecting systolic pressure are reviewed first.</p><p class="headingAnchor" id="H5"><span class="h2">Increases in systolic pressure</span><span class="headingEndMark"> — </span>Elevations in systolic pressure, particularly among older adults, are usually the result of stiffness in the large arteries as well as an early pulse wave reflection [<a href="#rid7">7,8</a>]. Although increases in peripheral vascular resistance appear to be a relatively more important component of hypertension in younger patients (30 to 49 years old), the role of peripheral vascular resistance in hypertension diminishes progressively with age [<a href="#rid1">1,9</a>]. Given the known effects of aging on vessel stiffness, increases in pulse pressure in older patients (eg, &gt;55 years of age) result from aortic stiffening, while increases in younger patients (ie, &lt;45 years of age) are more likely to result from increases in stroke volume. (See  <a class="medical medical_review" href="/z/d/html/3863.html" rel="external">"Treatment of hypertension in older adults, particularly isolated systolic hypertension", section on 'Isolated systolic hypertension'</a>.)</p><p class="headingAnchor" id="H6"><span class="h2">Decreases in diastolic pressure</span><span class="headingEndMark"> — </span>Since stiffening of the aorta with age reduces the elastic reservoir capacity, more blood runs off from each stroke volume during systole, resulting in a reduced blood volume within the aorta at the onset of diastole. This factor, when combined with diminished elastic recoil and an increased pressure decay rate, causes a fall in the diastolic pressure with age [<a href="#rid10">10</a>]. These changes in diastolic pressure (both in normotensive and hypertensive patients) become evident after the age of 55 years [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H7"><span class="h2">Genetics</span><span class="headingEndMark"> — </span>Increased pulse pressure may be a heritable trait [<a href="#rid11">11-15</a>]. As an example, a genome-wide association study that included more than 120,000 individuals of European ancestry found five loci that were significantly associated with pulse pressure, including three that had opposite effects on systolic and diastolic pressure [<a href="#rid12">12</a>]. One of these five loci, the fidgetin gene, was also associated with pulse pressure in an Asian cohort [<a href="#rid11">11</a>]. Other genetic studies have found a high degree of heritability (ranging from 20 to 40 percent) [<a href="#rid13">13,14</a>] with linkage to chromosome 18 in all ethnic groups, chromosome 19 in White patients, and chromosome 17 in Hispanic patients [<a href="#rid13">13</a>].</p><p class="headingAnchor" id="H8"><span class="h2">Other considerations</span><span class="headingEndMark"> — </span>Since a portion of the systolic pressure depends upon the height of the patient, shorter patients tend to have a higher pulse pressure. In addition, slower heart rates result in a greater pulse pressure.</p><p>In general, women are shorter than men but tend to have faster heart rates. As a result, differences in pulse pressure with sex are generally lacking since the effect of height on pulse pressure may be counterbalanced by the effect of heart rate.</p><p>Increasing evidence suggests that patients with metabolic syndrome have stiffer vessels, resulting in an increased pulse pressure [<a href="#rid16">16</a>].</p><p>Although it is generally thought that the aorta increases in size with age, some studies suggest that increases in pulse pressure are associated with reductions, not increases, in aortic diameter [<a href="#rid17">17</a>]. In one study of more than a thousand nondiabetic individuals who were free of cardiac disease, aortic root diameter determined by echocardiography was inversely related to pulse pressure [<a href="#rid17">17</a>]. These data suggest that aortic dimensions may contribute to, rather than result from, increased pulse pressure.</p><p class="headingAnchor" id="H9"><span class="h1">INCREASED PULSE PRESSURE AND ADVERSE OUTCOMES</span><span class="headingEndMark"> — </span>An increase in the pulse pressure places greater stress on arteries, resulting in fatigue and an increased fracture rate in the elastic components of the vessel wall. The vascular intima becomes prone to damage, thereby increasing the risk of atherosclerosis and thrombosis.</p><p class="headingAnchor" id="H53450682"><span class="h2">Pulse pressure and cardiovascular disease</span><span class="headingEndMark"> — </span>In addition to damage to the vascular wall, an increased pulse pressure is associated with increased stress on the left ventricle, which can result in ventricular hypertrophy and failure [<a href="#rid18">18,19</a>]. Heightened pressure during systole increases myocardial oxygen need, and the lower diastolic value may become a limiting factor for coronary perfusion, resulting in ischemia.</p><p>The net result of these combined effects is that increases in pulse pressure may be a predictor of a variety of adverse cardiovascular outcomes [<a href="#rid20">20</a>]. This association has been observed in numerous population-based cohort studies [<a href="#rid5">5,21-30</a>], among those undergoing coronary intervention [<a href="#rid31">31</a>], and in participants of randomized trials of hypertension treatment [<a href="#rid32">32-34</a>].</p><p>The following studies illustrate the range of findings from population-based cohorts, several of which included individuals with and without hypertension:</p><p class="bulletIndent1"><span class="glyph">●</span>In the Framingham Heart Study, for example, each 10 mmHg increment in pulse pressure was associated with a 23 percent higher risk of developing coronary heart disease (<a class="graphic graphic_figure graphicRef74090" href="/z/d/graphic/74090.html" rel="external">figure 1</a>) [<a href="#rid21">21</a>]. This association with pulse pressure was primarily seen in patients over the age of 50 years, particularly over the age of 60 years [<a href="#rid22">22</a>]. The adverse outcomes observed with an elevated pulse pressure in patients over the age of 50 years appear to apply to both normotensive and hypertensive patients, including those with low diastolic but normal systolic blood pressure [<a href="#rid23">23</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The association between pulse pressure and cardiovascular mortality was analyzed in over 340,000 men in the Multiple Risk Factor Intervention Trial (MRFIT) aged 35 to 57 years without preexisting diabetes or coronary heart disease followed for 22 years [<a href="#rid24">24</a>]. Systolic and diastolic pressures were stronger predictors of cardiovascular death than pulse pressure. However, pulse pressure was independently associated with risk, particularly among older men (aged 45 to 57 years). Among men younger than 45 years, pulse pressure was associated with mortality only in those with hypertension; among older men, pulse pressure was associated with an increased risk of death at any level of blood pressure. As an example, there was a 22 percent increased risk of cardiovascular mortality in the highest compared with lowest quartile of pulse pressure in men aged 45 years or older who had optimal blood pressure (defined as less than 120/80 mmHg).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other studies, such as the second National Health and Nutrition Examination Survey (NHANES), found that pulse pressure added little predictive value compared with either systolic or diastolic pressure [<a href="#rid5">5</a>]. Among 7830 individuals followed for 15 years, a higher pulse pressure was associated with either increased, decreased, or no change in the risk of cardiovascular and all-cause mortality depending upon age, systolic, and diastolic pressure. However, a subsequent study of NHANES data found that, among 8356 young adults 18 to 40 years of age, higher pulse pressure was independently associated with an increased risk of mortality at 12 years [<a href="#rid35">35</a>].</p><p></p><p>An association between pulse pressure and cardiovascular endpoints has also been observed in hypertension treatment trials, as illustrated by the following [<a href="#rid32">32,33</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In the Systolic Hypertension in the Elderly Program (SHEP) trial of older adult patients with isolated systolic hypertension, each 10 mmHg elevation in pulse pressure in the active treatment group was associated with increases in the risk for heart failure or stroke by 32 and 24 percent, respectively, after controlling for systolic pressure and other known risk factors [<a href="#rid32">32</a>]. However, pulse pressure was <strong>not</strong> associated with risk in patients assigned to placebo.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Twenty-four-hour ambulatory blood pressure recordings were obtained in the Systolic Hypertension in Europe (Syst-Eur) trial, also of older patients with isolated systolic hypertension [<a href="#rid33">33</a>]. In the placebo group, the ambulatory pulse pressure predicted all cardiovascular endpoints and stroke, as each 10 mmHg increase in pulse pressure was associated with a hazard ratio ranging from 1.25 to 1.68. In contrast to the finding from the SHEP trial, this relation was <strong>not</strong> significant in patients assigned active treatment.</p><p></p><p class="headingAnchor" id="H53450556"><span class="h2">Pulse pressure and diabetes</span><span class="headingEndMark"> — </span>The association between pulse pressure and the incidence of type 2 diabetes was examined in 2685 initially nondiabetic patients aged 20 to 84 years enrolled in the <a class="drug drug_general" data-topicid="8670" href="/z/d/drug information/8670.html" rel="external">Candesartan</a> Antihypertensive Survival Evaluation in Japan (CASE-J) trial [<a href="#rid36">36</a>]. Higher pulse pressure was significantly associated with an increased risk of developing diabetes (relative risk 1.44 for each 16 mmHg higher pulse pressure, 95% CI 1.15-1.79). Similarly, the pulse pressure divided by the mean arterial pressure, as a measure of vascular stiffness, was directly associated with diabetes risk. The mechanism underlying this association is unclear.</p><p>Consistent findings were observed in a cross-sectional study of 528 hypertensive patients from Italy who had both clinic and 24-hour ambulatory blood pressure measurements [<a href="#rid16">16</a>]. Clinic pulse pressure was significantly higher in patients with the metabolic syndrome compared with patients without the metabolic syndrome (61 versus 49 mmHg); results were similar for 24-hour ambulatory pulse pressure. Higher pulse pressure was also associated with individual components of the metabolic syndrome, including higher fasting serum glucose.</p><p class="headingAnchor" id="H53450570"><span class="h2">Pulse pressure and progression of chronic kidney disease</span><span class="headingEndMark"> — </span>Pulse pressure, as a reflection of arterial stiffness, may be an independent risk factor for progression of chronic kidney disease (CKD) [<a href="#rid37">37-41</a>]. The following studies illustrate the range of findings:</p><p class="bulletIndent1"><span class="glyph">●</span>The association between blood pressure components and risk of end-stage kidney disease (ESKD) was analyzed among 1513 patients with diabetic nephropathy in a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist <a class="drug drug_general" data-topicid="9574" href="/z/d/drug information/9574.html" rel="external">Losartan</a> (RENAAL) trial [<a href="#rid39">39</a>]. After controlling for multiple potential confounders, a 10 mmHg higher pulse pressure was significantly associated with a 17 percent higher relative risk of developing ESKD. A similar association was found for systolic but not diastolic pressure.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a study of 30,636 patients in Singapore followed for more than 11 years, higher pulse pressure was associated with ESKD even after adjusting for systolic and diastolic pressure (hazard ratio 1.28, 95% CI 1.11–1.47 for every 10 mmHg higher pulse pressure) [<a href="#rid41">41</a>].</p><p></p><p>In addition to reduced glomerular filtration rate, pulse pressure is also independently associated with urine protein excretion [<a href="#rid42">42,43</a>].</p><p class="headingAnchor" id="H10"><span class="h1">PULSE PRESSURE AND ANTIHYPERTENSIVE THERAPY</span><span class="headingEndMark"> — </span>Limited data suggest that antihypertensive agents differ in their effects on pulse pressure [<a href="#rid44">44</a>]. However, it is not appropriate to use pulse pressure as a factor in deciding which antihypertensive agent to employ or to use the measurement as a treatment endpoint itself [<a href="#rid34">34,45</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>In the <a class="drug drug_general" data-topicid="9574" href="/z/d/drug information/9574.html" rel="external">Losartan</a> Intervention For Endpoints (LIFE) trial comparing an angiotensin receptor blocker (ARB; losartan) with a beta blocker (<a class="drug drug_general" data-topicid="8940" href="/z/d/drug information/8940.html" rel="external">atenolol</a>), the risk of the composite endpoint (stroke, myocardial infarction, and cardiovascular death) rose significantly as pulse pressure increased in the atenolol group [<a href="#rid46">46</a>]. In the losartan group, the risk of the composite endpoint also rose across the pulse pressure quartiles, but the increase was not significant.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a retrospective analysis of the Veterans Affairs Single-Drug for Hypertension Study including 1292 men with a diastolic blood pressure of 95 to 109 mmHg at randomization, after one year of treatment, <a class="drug drug_general" data-topicid="8529" href="/z/d/drug information/8529.html" rel="external">hydrochlorothiazide</a> reduced pulse pressure by 8.6 mmHg, <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">clonidine</a> by 6.3 mmHg, <a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">diltiazem</a> by 5.5 mmHg, <a class="drug drug_general" data-topicid="9806" href="/z/d/drug information/9806.html" rel="external">prazosin</a> by 5 mmHg, <a class="drug drug_general" data-topicid="9196" href="/z/d/drug information/9196.html" rel="external">captopril</a> by 4.1 mmHg, and <a class="drug drug_general" data-topicid="8940" href="/z/d/drug information/8940.html" rel="external">atenolol</a> by 4.1 mmHg [<a href="#rid47">47</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the Conduit Artery Functional Evaluation (CAFE) substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT), 2073 participants underwent radial artery applanation tonometry and measurement of pulse wave velocity to calculate pulse pressure and central blood pressures [<a href="#rid48">48-51</a>]. The results suggested that <a class="drug drug_general" data-topicid="8940" href="/z/d/drug information/8940.html" rel="external">atenolol</a> had less central blood pressure reduction and improvement in pulse pressure, despite similar brachial artery blood pressure reduction, than a calcium channel blocker regimen [<a href="#rid48">48-50</a>]. Central pulse pressure was also associated with clinical outcomes [<a href="#rid51">51</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An analysis of data from clinical trials including more than 28,000 subjects suggested that the cardiovascular benefit of antihypertensive therapy was mostly linked to systolic blood pressure control [<a href="#rid52">52</a>]. In addition, the reduction in systolic pressure with treatment was found to be progressively larger than the reduction in diastolic blood pressure with increasing age (eg, greater fall in pulse pressure with increasing age) [<a href="#rid52">52</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the REASON (P<strong>re</strong>terax in regression of <strong>a</strong>rterial <strong>s</strong>tiffness in a contr<strong>o</strong>lled double-bli<strong>n</strong>d) study, patients randomly assigned to the <a class="drug drug_general" data-topicid="9758" href="/z/d/drug information/9758.html" rel="external">perindopril</a>/<a class="drug drug_general" data-topicid="8557" href="/z/d/drug information/8557.html" rel="external">indapamide</a> regimen showed greater pulse pressure decreases with treatment when metabolic syndrome was present (10 to 11 mmHg) than when metabolic syndrome was absent (2 to 3 mmHg) [<a href="#rid53">53,54</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a post hoc analysis of the Controlling and Lowering Blood Pressure With the MobiusHD (CALM II) trial, which compared <a class="drug drug_general" data-topicid="9565" href="/z/d/drug information/9565.html" rel="external">lisinopril</a> 40 mg to lisinopril 20 mg plus <a class="drug drug_general" data-topicid="8670" href="/z/d/drug information/8670.html" rel="external">candesartan</a> 16 mg daily in hypertensive diabetics, combination therapy produced a greater reduction in the pulse pressure compared with lisinopril alone as determined by ambulatory blood pressure monitoring (ABPM) [<a href="#rid55">55</a>]. The differences in pulse pressure were principally due to greater reductions in systolic pressure in the combination group. This study was not powered to assess outcome differences [<a href="#rid55">55</a>]. Further discussion of the CALM II trial can be found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3829.html" rel="external">"Treatment of hypertension in patients with diabetes mellitus"</a>.)</p><p></p><p>Further prospective research is required to define pulse pressure as a predictor of cardiovascular outcomes and to determine whether pulse pressure is a better index of response to therapy [<a href="#rid56">56,57</a>]. The pulse pressure probably best serves as a tool in clinical trials, to better illustrate the pharmacodynamic effects of drugs, and possibly to provide a sharpened estimate of overall cardiovascular disease risk [<a href="#rid56">56</a>]. A recent review that ties together the effects of age on pulse pressure and the role of pulse pressure in understanding cardiovascular risk in a general population is recommended for further reading [<a href="#rid20">20</a>].</p><p class="headingAnchor" id="H11"><span class="h1">CONCLUSIONS</span><span class="headingEndMark"> — </span>The literature appears to be divided on the prognostic values of the four measures of blood pressure: systolic, diastolic, mean, and pulse pressures. This arises in part because they are, basically, related to one another as they are all measures of the response in the circulation to each heartbeat. The value of one measure over another is strongly age-dependent and is also related to how variables are entered into statistical models that help predict cardiovascular outcomes.</p><p>The best use of pulse pressure at this time appears to be in providing help in revising the risk estimate of the systolic pressure in older individuals. Since systolic pressure predicts cardiovascular morbidity and mortality in older patients, clinicians are encouraged to revise upward the estimate of cardiovascular risk in older patients when the pulse pressure is increased [<a href="#rid58">58</a>]. A reasonable summation of our knowledge is that diastolic blood pressure is the best predictor of cardiovascular disease risk in the young (&lt;50 years), all three blood pressure components are equally predictive at ages 50 to 59 years, and pulse pressure is the best predictor from age 60 years and beyond.</p><p>Limited data also suggest that antihypertensive agents differ in their effects on pulse pressure [<a href="#rid44">44</a>]. However, it is premature to use pulse pressure as a factor in deciding which antihypertensive agent to employ or to use the measurement as a treatment endpoint itself [<a href="#rid45">45</a>].</p><p class="headingAnchor" id="H12"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span>Pulse pressure is <strong>defined</strong> as the systolic minus the diastolic pressure. (See <a class="local">'Clinical perspective'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Increased pulse pressure may be due to either or both an increase in systolic or a decrease in diastolic blood pressures. (See <a class="local">'Factors resulting in increased pulse pressure'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Among older patients, increased systolic pressure results from increased stiffness in the aorta and other large arteries; among younger patients, increased stroke volume plays a more important role. (See <a class="local">'Increases in systolic pressure'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Decreased diastolic pressure results from a reduction in aortic blood volume at the onset of diastole. This is related to the age-related decrease in elasticity of the aorta which causes more blood to run off during systole. (See <a class="local">'Decreases in diastolic pressure'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The pulse pressure is a good predictor of cardiovascular events among older adult patients and in some cases has superior predictive capability to that provided by systolic pressure alone. The best use of pulse pressure is in revising upward the risk estimate provided by the systolic pressure in older individuals. (See <a class="local">'Increased pulse pressure and adverse outcomes'</a> above and <a class="local">'Conclusions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Limited data suggest that different hypertensive agents may have varying effects on pulse pressure. (See <a class="local">'Pulse pressure and antihypertensive therapy'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Franklin SS, Gustin W 4th, Wong ND, et al. Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study. Circulation 1997; 96:308.</a></li><li><a class="nounderline abstract_t">Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 2018; 71:e13.</a></li><li><a class="nounderline abstract_t">Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens 2018; 36:1953.</a></li><li><a class="nounderline abstract_t">Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289:2560.</a></li><li><a class="nounderline abstract_t">Pastor-Barriuso R, Banegas JR, Damián J, et al. Systolic blood pressure, diastolic blood pressure, and pulse pressure: an evaluation of their joint effect on mortality. Ann Intern Med 2003; 139:731.</a></li><li><a class="nounderline abstract_t">Gavish B, Bursztyn M. Ambulatory pulse pressure components: concept, determination and clinical relevance. J Hypertens 2019; 37:765.</a></li><li><a class="nounderline abstract_t">Nichols WW, Nicolini FA, Pepine CJ. Determinants of isolated systolic hypertension in the elderly. J Hypertens Suppl 1992; 10:S73.</a></li><li><a class="nounderline abstract_t">O'Rourke MF, Nichols WW. Aortic diameter, aortic stiffness, and wave reflection increase with age and isolated systolic hypertension. Hypertension 2005; 45:652.</a></li><li><a class="nounderline abstract_t">Messerli FH, Sundgaard-Riise K, Ventura HO, et al. Essential hypertension in the elderly: haemodynamics, intravascular volume, plasma renin activity, and circulating catecholamine levels. Lancet 1983; 2:983.</a></li><li><a class="nounderline abstract_t">Folkow B. Structure and function of the arteries in hypertension. Am Heart J 1987; 114:938.</a></li><li><a class="nounderline abstract_t">Kato N, Takeuchi F, Tabara Y, et al. Meta-analysis of genome-wide association studies identifies common variants associated with blood pressure variation in east Asians. Nat Genet 2011; 43:531.</a></li><li><a class="nounderline abstract_t">Wain LV, Verwoert GC, O'Reilly PF, et al. Genome-wide association study identifies six new loci influencing pulse pressure and mean arterial pressure. Nat Genet 2011; 43:1005.</a></li><li><a class="nounderline abstract_t">Bielinski SJ, Lynch AI, Miller MB, et al. Genome-wide linkage analysis for loci affecting pulse pressure: the Family Blood Pressure Program. Hypertension 2005; 46:1286.</a></li><li><a class="nounderline abstract_t">Hsu FC, Zaccaro DJ, Lange LA, et al. The impact of pedigree structure on heritability estimates for pulse pressure in three studies. Hum Hered 2005; 60:63.</a></li><li><a class="nounderline abstract_t">Pettersson-Fernholm K, Fröjdö S, Fagerudd J, et al. The AT2 gene may have a gender-specific effect on kidney function and pulse pressure in type I diabetic patients. Kidney Int 2006; 69:1880.</a></li><li><a class="nounderline abstract_t">Mulè G, Nardi E, Cottone S, et al. Relationship of metabolic syndrome with pulse pressure in patients with essential hypertension. Am J Hypertens 2007; 20:197.</a></li><li><a class="nounderline abstract_t">Farasat SM, Morrell CH, Scuteri A, et al. Pulse pressure is inversely related to aortic root diameter implications for the pathogenesis of systolic hypertension. Hypertension 2008; 51:196.</a></li><li><a class="nounderline abstract_t">O'Rourke M, Frohlich ED. Pulse pressure: Is this a clinically useful risk factor? Hypertension 1999; 34:372.</a></li><li><a class="nounderline abstract_t">Winston GJ, Palmas W, Lima J, et al. Pulse pressure and subclinical cardiovascular disease in the multi-ethnic study of atherosclerosis. Am J Hypertens 2013; 26:636.</a></li><li><a class="nounderline abstract_t">Melgarejo JD, Thijs L, Wei DM, et al. Relative and Absolute Risk to Guide the Management of Pulse Pressure, an Age-Related Cardiovascular Risk Factor. Am J Hypertens 2021; 34:929.</a></li><li><a class="nounderline abstract_t">Franklin SS, Khan SA, Wong ND, et al. Is pulse pressure useful in predicting risk for coronary heart Disease? The Framingham heart study. Circulation 1999; 100:354.</a></li><li><a class="nounderline abstract_t">Franklin SS, Larson MG, Khan SA, et al. Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study. Circulation 2001; 103:1245.</a></li><li><a class="nounderline abstract_t">Thomas F, Blacher J, Benetos A, et al. Cardiovascular risk as defined in the 2003 European blood pressure classification: the assessment of an additional predictive value of pulse pressure on mortality. J Hypertens 2008; 26:1072.</a></li><li><a class="nounderline abstract_t">Domanski M, Mitchell G, Pfeffer M, et al. Pulse pressure and cardiovascular disease-related mortality: follow-up study of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 2002; 287:2677.</a></li><li><a class="nounderline abstract_t">Franklin SS, Lopez VA, Wong ND, et al. Single versus combined blood pressure components and risk for cardiovascular disease: the Framingham Heart Study. Circulation 2009; 119:243.</a></li><li><a class="nounderline abstract_t">Lorenzo C, Aung K, Stern MP, Haffner SM. Pulse pressure, prehypertension, and mortality: the San Antonio heart study. Am J Hypertens 2009; 22:1219.</a></li><li><a class="nounderline abstract_t">Okada K, Iso H, Cui R, et al. Pulse pressure is an independent risk factor for stroke among middle-aged Japanese with normal systolic blood pressure: the JPHC study. J Hypertens 2011; 29:319.</a></li><li><a class="nounderline abstract_t">Panagiotakos DB, Kromhout D, Menotti A, et al. The relation between pulse pressure and cardiovascular mortality in 12,763 middle-aged men from various parts of the world: a 25-year follow-up of the seven countries study. Arch Intern Med 2005; 165:2142.</a></li><li><a class="nounderline abstract_t">Assmann G, Cullen P, Evers T, et al. Importance of arterial pulse pressure as a predictor of coronary heart disease risk in PROCAM. Eur Heart J 2005; 26:2120.</a></li><li><a class="nounderline abstract_t">Sobiczewski W, Wirtwein M, Jarosz D, et al. Increased total mortality as a function of 24-h pulse pressure dipping. J Hum Hypertens 2016; 30:100.</a></li><li><a class="nounderline abstract_t">Warren J, Nanayakkara S, Andrianopoulos N, et al. Impact of Pre-Procedural Blood Pressure on Long-Term Outcomes Following Percutaneous Coronary Intervention. J Am Coll Cardiol 2019; 73:2846.</a></li><li><a class="nounderline abstract_t">Vaccarino V, Berger AK, Abramson J, et al. Pulse pressure and risk of cardiovascular events in the systolic hypertension in the elderly program. Am J Cardiol 2001; 88:980.</a></li><li><a class="nounderline abstract_t">Staessen JA, Thijs L, O'Brien ET, et al. Ambulatory pulse pressure as predictor of outcome in older patients with systolic hypertension. Am J Hypertens 2002; 15:835.</a></li><li><a class="nounderline abstract_t">Pareek M, Vaduganathan M, Biering-Sørensen T, et al. Pulse Pressure, Cardiovascular Events, and Intensive Blood-Pressure Lowering in the Systolic Blood Pressure Intervention Trial (SPRINT). Am J Med 2019; 132:733.</a></li><li><a class="nounderline abstract_t">Li J, Huang JY, Lo K, et al. Association of pulse pressure with all-cause mortality in young adults. Postgrad Med J 2020; 96:461.</a></li><li><a class="nounderline abstract_t">Yasuno S, Ueshima K, Oba K, et al. Is pulse pressure a predictor of new-onset diabetes in high-risk hypertensive patients?: a subanalysis of the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial. Diabetes Care 2010; 33:1122.</a></li><li><a class="nounderline abstract_t">Muntner P, Anderson A, Charleston J, et al. Hypertension awareness, treatment, and control in adults with CKD: results from the Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis 2010; 55:441.</a></li><li><a class="nounderline abstract_t">Arulkumaran N, Diwakar R, Tahir Z, et al. Pulse pressure and progression of chronic kidney disease. J Nephrol 2010; 23:189.</a></li><li><a class="nounderline abstract_t">Bakris GL, Weir MR, Shanifar S, et al. Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study. Arch Intern Med 2003; 163:1555.</a></li><li><a class="nounderline abstract_t">Tanaka M, Babazono T, Takeda M, Iwamoto Y. Pulse pressure and chronic kidney disease in patients with type 2 diabetes. Hypertens Res 2006; 29:345.</a></li><li><a class="nounderline abstract_t">Geng TT, Talaei M, Jafar TH, et al. Pulse Pressure and the Risk of End-Stage Renal Disease Among Chinese Adults in Singapore: The Singapore Chinese Health Study. J Am Heart Assoc 2019; 8:e013282.</a></li><li><a class="nounderline abstract_t">Weir MR, Townsend RR, Fink JC, et al. Hemodynamic correlates of proteinuria in chronic kidney disease. Clin J Am Soc Nephrol 2011; 6:2403.</a></li><li><a class="nounderline abstract_t">Kim JK, Ju YS, Moon SJ, et al. High pulse pressure and metabolic syndrome are associated with proteinuria in young adult women. BMC Nephrol 2013; 14:45.</a></li><li><a class="nounderline abstract_t">Domanski MJ, Davis BR, Pfeffer MA, et al. Isolated systolic hypertension : prognostic information provided by pulse pressure. Hypertension 1999; 34:375.</a></li><li><a class="nounderline abstract_t">Izzo JL Jr, Levy D, Black HR. Clinical Advisory Statement. Importance of systolic blood pressure in older Americans. Hypertension 2000; 35:1021.</a></li><li><a class="nounderline abstract_t">Fyhrquist F, Dahlöf B, Devereux RB, et al. Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophy. Hypertension 2005; 45:580.</a></li><li><a class="nounderline abstract_t">Cushman WC, Materson BJ, Williams DW, Reda DJ. Pulse pressure changes with six classes of antihypertensive agents in a randomized, controlled trial. Hypertension 2001; 38:953.</a></li><li><a class="nounderline abstract_t">Williams B, O'Rourke M, Anglo-Scandinavian Cardiac Outcomes Trial. The Conduit Artery Functional Endpoint (CAFE) study in ASCOT. J Hum Hypertens 2001; 15 Suppl 1:S69.</a></li><li><a class="nounderline abstract_t">Katakam R, Townsend RR. What's in a pulse? J Clin Hypertens (Greenwich) 2006; 8:140.</a></li><li><a class="nounderline abstract_t">Dahlöf B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366:895.</a></li><li><a class="nounderline abstract_t">Williams B, Lacy PS, Thom SM, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006; 113:1213.</a></li><li><a class="nounderline abstract_t">Wang JG, Staessen JA, Franklin SS, et al. Systolic and diastolic blood pressure lowering as determinants of cardiovascular outcome. Hypertension 2005; 45:907.</a></li><li><a class="nounderline abstract_t">London GM, Asmar RG, O'Rourke MF, et al. Mechanism(s) of selective systolic blood pressure reduction after a low-dose combination of perindopril/indapamide in hypertensive subjects: comparison with atenolol. J Am Coll Cardiol 2004; 43:92.</a></li><li><a class="nounderline abstract_t">Safar ME. Pulse pressure: a help in medical semiology for metabolic syndrome. Am J Hypertens 2007; 20:204.</a></li><li><a class="nounderline abstract_t">Knudsen ST, Andersen NH, Poulsen SH, et al. Pulse pressure lowering effect of dual blockade with candesartan and lisinopril vs. high-dose ACE inhibition in hypertensive type 2 diabetic subjects: a CALM II study post-hoc analysis. Am J Hypertens 2008; 21:172.</a></li><li><a class="nounderline abstract_t">Oparil S, Izzo JL Jr. Pulsology rediscovered: commentary on the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006; 113:1162.</a></li><li><a class="nounderline abstract_t">Wilkinson IB, McEniery CM, Cockcroft JR. Atenolol and cardiovascular risk: an issue close to the heart. Lancet 2006; 367:627.</a></li><li><a class="nounderline abstract_t">Franklin SS. Ageing and hypertension: the assessment of blood pressure indices in predicting coronary heart disease. J Hypertens Suppl 1999; 17:S29.</a></li></ol></div><div id="topicVersionRevision">Topic 3858 Version 29.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9236450" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29133356" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30234752" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12748199" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14597457" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Systolic blood pressure, diastolic blood pressure, and pulse pressure: an evaluation of their joint effect on mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30817458" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Ambulatory pulse pressure components: concept, determination and clinical relevance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1432333" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Determinants of isolated systolic hypertension in the elderly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15699456" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Aortic diameter, aortic stiffness, and wave reflection increase with age and isolated systolic hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6138591" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Essential hypertension in the elderly: haemodynamics, intravascular volume, plasma renin activity, and circulating catecholamine levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3661386" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Structure and function of the arteries in hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21572416" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Meta-analysis of genome-wide association studies identifies common variants associated with blood pressure variation in east Asians.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21909110" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Genome-wide association study identifies six new loci influencing pulse pressure and mean arterial pressure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16286574" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Genome-wide linkage analysis for loci affecting pulse pressure: the Family Blood Pressure Program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16155398" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The impact of pedigree structure on heritability estimates for pulse pressure in three studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16598200" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The AT2 gene may have a gender-specific effect on kidney function and pulse pressure in type I diabetic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17261467" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Relationship of metabolic syndrome with pulse pressure in patients with essential hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18158348" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Pulse pressure is inversely related to aortic root diameter implications for the pathogenesis of systolic hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10489378" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Pulse pressure: Is this a clinically useful risk factor?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23388832" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Pulse pressure and subclinical cardiovascular disease in the multi-ethnic study of atherosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33687055" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Relative and Absolute Risk to Guide the Management of Pulse Pressure, an Age-Related Cardiovascular Risk Factor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10421594" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Is pulse pressure useful in predicting risk for coronary heart Disease? The Framingham heart study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11238268" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18475143" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Cardiovascular risk as defined in the 2003 European blood pressure classification: the assessment of an additional predictive value of pulse pressure on mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12020303" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Pulse pressure and cardiovascular disease-related mortality: follow-up study of the Multiple Risk Factor Intervention Trial (MRFIT).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19118251" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Single versus combined blood pressure components and risk for cardiovascular disease: the Framingham Heart Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19696747" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Pulse pressure, prehypertension, and mortality: the San Antonio heart study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21150641" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Pulse pressure is an independent risk factor for stroke among middle-aged Japanese with normal systolic blood pressure: the JPHC study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16217005" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : The relation between pulse pressure and cardiovascular mortality in 12,763 middle-aged men from various parts of the world: a 25-year follow-up of the seven countries study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16141262" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Importance of arterial pulse pressure as a predictor of coronary heart disease risk in PROCAM.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25924909" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Increased total mortality as a function of 24-h pulse pressure dipping.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31171090" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Impact of Pre-Procedural Blood Pressure on Long-Term Outcomes Following Percutaneous Coronary Intervention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11703993" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Pulse pressure and risk of cardiovascular events in the systolic hypertension in the elderly program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12372669" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Ambulatory pulse pressure as predictor of outcome in older patients with systolic hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30659811" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Pulse Pressure, Cardiovascular Events, and Intensive Blood-Pressure Lowering in the Systolic Blood Pressure Intervention Trial (SPRINT).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31780595" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Association of pulse pressure with all-cause mortality in young adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20185746" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Is pulse pressure a predictor of new-onset diabetes in high-risk hypertensive patients?: a subanalysis of the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19962808" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Hypertension awareness, treatment, and control in adults with CKD: results from the Chronic Renal Insufficiency Cohort (CRIC) Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20119928" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Pulse pressure and progression of chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12860578" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16832155" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Pulse pressure and chronic kidney disease in patients with type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31766974" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Pulse Pressure and the Risk of End-Stage Renal Disease Among Chinese Adults in Singapore: The Singapore Chinese Health Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21852669" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Hemodynamic correlates of proteinuria in chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23433013" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : High pulse pressure and metabolic syndrome are associated with proteinuria in young adult women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10489379" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Isolated systolic hypertension : prognostic information provided by pulse pressure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10818056" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Clinical Advisory Statement. Importance of systolic blood pressure in older Americans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15790960" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11641316" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Pulse pressure changes with six classes of antihypertensive agents in a randomized, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11685915" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : The Conduit Artery Functional Endpoint (CAFE) study in ASCOT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16470084" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : What's in a pulse?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16154016" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16476843" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15837826" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Systolic and diastolic blood pressure lowering as determinants of cardiovascular outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14715189" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Mechanism(s) of selective systolic blood pressure reduction after a low-dose combination of perindopril/indapamide in hypertensive subjects: comparison with atenolol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17261468" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Pulse pressure: a help in medical semiology for metabolic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18188164" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Pulse pressure lowering effect of dual blockade with candesartan and lisinopril vs. high-dose ACE inhibition in hypertensive type 2 diabetic subjects: a CALM II study post-hoc analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16520424" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Pulsology rediscovered: commentary on the Conduit Artery Function Evaluation (CAFE) study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16503444" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Atenolol and cardiovascular risk: an issue close to the heart.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10706323" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Ageing and hypertension: the assessment of blood pressure indices in predicting coronary heart disease.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
